Zentek Ltd. (ZTEKF): Financial results for FY2027

Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze

Event · Earnings
Original reporting
Published Nov 17, 2026, 2:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ZTEKF
Bullish
medium confidence
Mentioned
$ZTEKF
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$ZTEKFBullishMed
01

Why it matters

The release emphasizes a strengthened balance sheet after May 2026 financing, reports cash and working capital at September 30, 2026, and ties reported profitability to a non-cash impairment reversal tied to an updated Albany PEA and FVLCD estimate.

02

Market read

Traders can reassess near-term liquidity and project de-risking progress using the disclosed cash/working-capital figures and the earnings bridge that separates non-cash impairment effects from operating performance.

03

What to watch

Working capital improved after the May 2026 financing, so the key risk is whether future ZenGUARD order growth and Albany de-risking can translate into cash generation before additional dilution.

Relevance 7/10Novelty 6/10Timing: filed pre-market today (SEC 6-K earnings release)

Background

Zentek is an advanced materials IP commercialization company with platforms including ZenGUARD filters and the Albany Graphite Project; it also holds aptamer-based technologies via Triera Biosciences.

Company-level read

Ticker impact

$ZTEKFBullishMedium confidence
Context

Zentek reports Q2 FY2027 results with cash rising to $13.6M and a $19.7M non-cash Albany Graphite impairment reversal.

Expected impact

Likely modest positive bias as investors focus on improved liquidity and progress toward Albany and ZenGUARD commercialization, offset by ongoing operating losses.

Evidence & confidence

The filing provides concrete liquidity metrics (cash and working capital) and a clear bridge from net income to loss excluding the non-cash reversal, which should shape near-term sentiment.

Market effects

Highlights ongoing financing and de-risking dynamics for small-cap advanced materials and graphite development stories.

Relevant to Canadian micro/small-cap investors tracking TSXV/OTCQX issuers’ liquidity and project milestones.

Limited beyond niche commodity/materials and specialty filtration technology investor communities.

Counterpoint

The headline net income is largely driven by a non-cash impairment reversal, while operating expenses and cash burn indicate the core business still needs execution and funding.

Key entities

  • Zentek Ltd.

    Reports Q2 FY2027 results, cash and working capital improvement, and an impairment reversal related to the Albany Graphite Project.

  • Albany Graphite Project

    100% owned project in Northern Ontario; impairment reversal recognized after updated PEA and mineral resource estimate.

  • ZenGUARD™

    Specialty coating for filters and PPE; management cites selling in Canada and the United States and ongoing order growth.

Related articles

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.

$RIMEMed

Algorhythm Holdings Reports Third Quarter 2026 Financial Results

Algorhythm Holdings, Inc. (RIME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Algorhythm Holdings Reports Third Quarter 2026 Financial Results Company Completes Azure Energy Acquisition and Begins Strategic Restructuring Fort Lauderdale, FL, November 17, 2026 – Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME ), a diversified holding co

$JDMedAI 8/10

JD.com returns to revenue growth as third-quarter profit misses estimates

JD.com reported Q3 revenue growth of 3.5% to 309.59 billion yuan, beating estimates. Net income rose 23% to 6.5 billion yuan but missed expectations. Electronics revenue fell 0.7%, while general merchandise rose 8.1%. Operating income turned positive. Shares fell in premarket trading. The company expanded its user base and completed a stake acquisition in Ceconomy.